PMID- 23219441 OWN - NLM STAT- MEDLINE DCOM- 20131018 LR - 20161125 IS - 1618-0372 (Electronic) IS - 0065-1281 (Linking) VI - 115 IP - 5 DP - 2013 Jun TI - Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information. PG - 452-9 LID - S0065-1281(12)00144-4 [pii] LID - 10.1016/j.acthis.2012.10.009 [doi] AB - Papillary renal cell carcinoma (PRCC) includes two different morphological subtypes. The differences of genetics and ultrastructure of the two subtypes have been rarely reported. Also, new biomarkers related to the diagnosis and prognosis of PRCC have still not been well elucidated. Immunohistochemistry, fluorescence in situ hybridization (FISH) and transmission electron microscopy were used systematically to determine the characteristics of 56 cases of PRCC and to reveal new diagnostic and prognostic information. Type 1 PRCC presented higher expression rates of EMA and CK7, whereas type 2 presented a higher expression rate of CD10. New immunohistochemical markers, including: p504s, PAX-2, PAX-8 and CA-IX showed extensive immunostaining in PRCC. We first revealed a distinct immunostaining pattern of CA-IX, which was located in multiple foci in PRCC. All tumors had at least one chromosomal aberration including loss of Y, gains of 7 or 17. Gain of chromosome 17 was common in type 1; losses of chromosome 18, 11 and 8 appeared in type 2. Ultrastructurally, glycogen granules and secondary lysosomes were seen in type 1, mitochondria and smooth endoplasmic reticulum were scattered in type 2. Tumor subtype, nuclear grade, TNM stage, clear cell renal cell carcinoma (CCRCC) component and sarcomatoid elements, metastasis, CAIX expression, losses of chromosome 18 and 8 were related to poor outcome of PRCC. We conclude that the two subtypes of PRCC originate from different renal cells, and arise from partially common genetic pathways. EMA, CK7, CD10, p504s, PAX-2, PAX-8 and CA-IX are helpful markers in the differential diagnosis of PRCC. CA-IX expression, losses of chromosome 18 and 8 are new prognostic factors of PRCC. CI - Copyright (c) 2012 Elsevier GmbH. All rights reserved. FAU - Yu, Wenjuan AU - Yu W AD - Department of Pathology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, PR China. FAU - Zhang, Wei AU - Zhang W FAU - Jiang, Yanxia AU - Jiang Y FAU - Wang, Yuewei AU - Wang Y FAU - Li, Yujun AU - Li Y FAU - Wang, Jigang AU - Wang J FAU - Sun, Lingling AU - Sun L FAU - Ran, Wenwen AU - Ran W FAU - Li, Hong AU - Li H LA - eng PT - Journal Article DEP - 20121207 PL - Germany TA - Acta Histochem JT - Acta histochemica JID - 0370320 RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) RN - 9005-79-2 (Glycogen) RN - EC 4.2.1.1 (CA9 protein, human) RN - EC 4.2.1.1 (Carbonic Anhydrase IX) RN - EC 4.2.1.1 (Carbonic Anhydrases) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antigens, Neoplasm/metabolism MH - Biomarkers, Tumor/metabolism MH - Carbonic Anhydrase IX MH - Carbonic Anhydrases/metabolism MH - Carcinoma, Renal Cell/*diagnosis/*genetics MH - *Chromosome Aberrations MH - Endoplasmic Reticulum, Smooth/ultrastructure MH - Female MH - Glycogen/ultrastructure MH - Humans MH - In Situ Hybridization, Fluorescence MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/*diagnosis/*genetics MH - Lysosomes/ultrastructure MH - Male MH - Microscopy, Electron, Transmission MH - Middle Aged MH - Mitochondria/ultrastructure MH - Prognosis MH - Survival Rate EDAT- 2012/12/12 06:00 MHDA- 2013/10/19 06:00 CRDT- 2012/12/11 06:00 PHST- 2012/07/29 00:00 [received] PHST- 2012/10/24 00:00 [revised] PHST- 2012/10/25 00:00 [accepted] PHST- 2012/12/11 06:00 [entrez] PHST- 2012/12/12 06:00 [pubmed] PHST- 2013/10/19 06:00 [medline] AID - S0065-1281(12)00144-4 [pii] AID - 10.1016/j.acthis.2012.10.009 [doi] PST - ppublish SO - Acta Histochem. 2013 Jun;115(5):452-9. doi: 10.1016/j.acthis.2012.10.009. Epub 2012 Dec 7.